Nicox announced on Friday that royalties received on Vyzulta, its ophthalmic solution licensed to Bausch + Lomb, had exceeded the four-million-euro threshold for the first time in 2023.

The pharmaceutical company reports that its sales thus amounted to 4.2 million euros last year, an increase of 29% on the 3.3 million euros recorded in fiscal 2022.

At December 31, Nicox had cash and cash equivalents of 11.9 million, compared with 27.7 million a year earlier, an amount deemed sufficient to ensure its financing until June 2024, based exclusively on the development of NCX 470.

This novel nitric oxide-donating prostaglandin analog is being studied for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension

In its press release, the company states that it is pursuing licensing discussions and other revenue-generating agreements, while studying several strategic options and holding discussions with its creditors to restructure its debt, which stands at 21 million euros.

Nicox stresses, however, that the approval and commercialization of Zerviate (allergic conjunctivitis), scheduled for China in 2024, should also contribute to an increase in sales from collaborations.

Listed on the Paris Bourse, Nicox shares were up 0.8% at mid-session on Thursday, following this unsurprising publication.

Copyright (c) 2024 CercleFinance.com. All rights reserved.